Global Hyperkalemia Drugs (Acute & Chronic) Market 2019-2023 - ResearchAndMarkets.com
Wednesday, 09 January 2019 05:06
Jan. 9, 2019 13:29 UTC

Global Hyperkalemia Drugs (Acute & Chronic) Market 2019-2023 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Global Hyperkalemia Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The hyperkalemia drugs market will grow at a CAGR of more than 20% during the forecast period.

The growing cases of various chronic diseases such as chronic kidney diseases and cardiovascular-related disorders are driving the market growth. Chronic kidney diseases increase the risk of patient developing hyperkalemia significantly, as the kidneys lose the ability to excrete potassium through urine. The ability of kidneys to excrete potassium decreases with time, which increases the risk of hyperkalemia becoming acute. Similarly, cardiovascular-related disorders also increase the risk of hyperkalemiain people. Hence, the increasing prevalence of these diseases is expected to contribute heavily of the growth of the market during the forecast.

Market Overview

Increasing prevalence of hyperkalemia

The global hyperkalemia drugs market has witnessed a growth in recent years, primarily due to the increasing prevalence of the disease globally. The recurring nature of the disease is another factor that is expected to contribute to the huge unmet need globally. Due to the increasing prevalence and the huge unmet need, the market has witnessed the approval of novel drugs.

Lack of approved therapies

The treatment using these therapies is known to decrease the potassium levels in the blood only to a certain extent. Due to the presence of a limited number of approved therapies, the market has huge growth potential; however the pipeline for hyperkalemia is weak, with only two molecules bring studied currently. These molecules are in the pre-clinical stages of development and are not expected to enter the market during the forecast period.

Competitive Landscape

The global hyperkalemia drugs market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Comparison by type
  • Chronic hyperkalemia
  • Acute hyperkalemia
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma

For more information about this report visit https://www.researchandmarkets.com/research/tkdb6m/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter